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Charles Weissmann’s new office,
squeezed into the corner of a London
laboratory, seems in every sense too
small for him. An imposing physical
presence, his intellect also dominates
the space with the kind of energy that
can scarcely veil its impatience.
Weissmann, best known today for
his contributions to the molecular
biology of prion diseases such as
scrapie and BSE, came to work at
Imperial College School of Medicine
at St Mary’s in March, at the
invitation of Britain’s Medical
Research Council. He had just retired
from the University of Zurich in his
native Switzerland, as director of the
Institute of Molecular Biology which
he founded 32 years ago. He is almost
68 but you could mistake him for a
man 15 years younger. Perhaps this is
because, by his own admission, he
likes to challenge himself.
Not many people in their late
sixties would give up a lifestyle that
includes weekend skiing for the noise
and frustration of London, but
Weissmann is relishing the change.
He had, in any case, vowed not to stay
in his former department in a
different role. “It is very disturbing
for a successor to have his predecessor
hanging around, trying to be a sort of
éminence grise,” he explains, grinning
briefly at the thought. Originally, the
MRC had wanted him to set up a new
group in Cambridge. But he did not
want to find himself in competition
with John Collinge, head of the
neurogenetics group at Imperial
College, so he opted to join Collinge’s
group instead.
Weissmann’s fascination with the
spongiform encephalopathies began
when he heard Stanley Prusiner talk
on the subject in Perth, Australia, in
1982. Since then, his contributions
have been critical. In particular, he
and his colleagues cloned the gene
that encodes the prion protein, PrP, in
1985 and then, between 1990 and
1992, made knockout mice lacking
functional PrP genes and showed
that these animals were resistant to
scrapie infection and incapable of
propagating the scrapie agent. Then,
in 1995, Weissmann showed that,
when PrP genes were put back into
the animals, they became susceptible
to infection again.
These experiments
went a long way
towards convincing
sceptics of the
seriousness of the
controversial
‘protein-only
hypothesis’: the idea
that a protein without
nucleic acids could be
an infectious agent.
But Weissmann is
far from
complacent.
He is quick to
emphasize his
respect for a
number of
heavyweight
researchers
who reject the
hypothesis and fall
into the other camp,
believing that a
virus-like entity,
sometimes called a virino, must be
the causal agent. Even for those who
agree with him that prions are central
to infection, he warns, there are still
unanswered questions. For example,
there is a growing consensus that the
prion protein must be accompanied
by some other protein or chaperone
molecule in the process of infection
— but, as yet, no one knows what it
is. One key challenge, Weissmann
says, is to generate measurable prion
infectivity in vitro.
Former colleagues are not
surprised at Weissmann’s
unwillingness to rest on his laurels.
“Charles is an incredibly rigorous
person,” says Richard Flavell at Yale
University. “He is almost obsessive
about making sure that he is right.”
Flavell first worked with Weissmann
as a postdoc in the early 1970s, when
they interacted on an almost daily
basis for a year and a half, which
might have been too intense for many
people. “Charles is a very strong
personality and doesn’t tolerate fools
readily.” Yet, although Weissmann
could be harsh on his students, he
always had a keen sense of humour,
says Flavell, and the
two got on well and
continued to
collaborate for years
afterwards.
But for others,
such as Esteban
Domingo, now at the
Universidad
Autónoma de Madrid,
it was a case of
developing what he
calls “adaptive
strategies to survive
under the domination
of Charles.” Domingo
says he learnt from
fellow postdocs how to
show Weissmann his
intense involvement
in his research, for
example by adopting
expressions of intense
joy if an experiment
worked, and deep
sadness if it did not.
If he has a reputation for driving
students hard, he also dislikes the
slower reaches of molecular biology.
Heidi Diggelmann, now at the
University of Lausanne, worked in
Weissmann’s lab in the late 1960s,
studying avian retroviruses. She says
he found retroviral research too slow.
“Experiments with bacteriophages
corresponded better to his impatient
temperament.”
Weissmann, born into a Jewish
family, was still a child when his
father, fearing a Nazi invasion of
Switzerland, took the household to
Rio de Janeiro in 1941. Five years
later they returned to Switzerland but
in the meantime Charles had
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attended a Portuguese-speaking
school. Had the five years in Rio been
a brake on his education? “On the
contrary,” he says. “I was challenged
by having to continue my studies
while also learning the language.”
It hardly held him back. After
earning degrees in medicine and
biochemistry at Zurich, he went to
the US in 1961. At New York
University, he studied RNA phage
replication, focusing on the RNA
bacteriophage Qβ, which has only
4,300 nucleotides. (He remarks wryly
that much of the molecular biology of
Qβ remains unknown, and wonders
aloud how some researchers can talk
seriously about understanding
100,000 human genes.)
By 1967 he was back in Zurich,
heading the institute, and in 1978 he
and other leading molecular biologists
founded the company Biogen. As he
was already working in the institute
on the cloning of mouse interferon,
his group was commissioned by
Biogen to clone human interferon
cDNA. Success came unexpectedly
over Christmas 1979; Weissmann,
who had left the lab for a few days’
skiing with the family, recounts how
he heard the news in a call-box on top
of a mountain, before rushing back to
spend the rest of the holiday in the
lab. Although his time with Biogen
was enjoyable, 10 years were enough
and from the late 1980s he was ready
to concentrate again on basic research.
In fact, Weissmann not only
enjoys basic research but also feels
passionate about defending it. “One
should cultivate basic research as one
cultivates the arts,” he says — and, as
a fan of twentieth-century art and of
the work of members of the London
School, such as Francis Bacon, he is
better placed than many colleagues to
know what this means.
And his next project? Well, he
gives himself about five years in
London, then he will return to
Switzerland. “I think that would be a
good time to stop.” But will he?
Phyllida Brown is a science writer based
in London.
The amplification of
oncogenes in human
tumours is often
mediated by little bits of
extra-chromosomal DNA called
double-minute chromosomes (DMs).
If cancer cells lose these DMs, the
cells revert to a normal growth
pattern and become more susceptible
to chemotherapy.
The larger image above shows a
prometaphase spread of a cell from a
colon cancer cell line in which DMs
(containing c-myc oncogenes) have
been labelled yellow and
chromosomal DNA counterstained
red. Importantly, the DMs are not
distributed randomly; they cluster
around the periphery of the
prometaphase ring.
DMs can be removed from the
nucleus by a molecular mechanism
known as micronucleation, which is
initiated by nuclear budding during
S phase of the cell cycle. The inset
image shows one of
these nuclear buds (at
bottom right) in which
the DMs (yellow) have been
selectively entrapped. The rate of
micronucleation can be increased by
the addition of replication inhibitors
and, in normal human cells, is
increased by inactivating the tumour
suppressor p53. Such studies might
help in the development of new
strategies to encourage tumour cells
to revert to normal growth by getting
rid of their DMs.
For further details, see J Cell Biol
1998, 140:1307-1320 and Curr Biol
1998, 8:377-385. Images reproduced
with permission from J Cell Biol and
provided by N. Shimizu, Faculty of
Integrated Arts and Sciences,
Hiroshima University, Kagamiyama
1-7-1, Higashi-Hiroshima 739-8521,
Japan and G. Wahl, The Salk
Institute, 10010 North Torrey Pines
Road, La Jolla, California 92037, USA.
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